EORTC QLU-C10D value sets for Austria, Italy, and Poland

Abstract

Objective To develop Austrian, Italian, and Polish general population value sets for the EORTC QLU-C10D, a cancer-specific utility instrument based on the EORTC QLQ-C30, and to descriptively compare their index scores for distinct health states. Methods The QLU-C10D descriptive system comprises 10 health attributes and each can take on 4 levels. A standardised and pre-tested methodology has been applied for valuations including a web-based discrete choice experiment (DCE). It was administered in 1000 general population respondents per country recruited via online panels, aiming at representativeness for core socio-demographic variables. Results In all three countries, the attributes with the largest impact on utility were physical functioning, pain, and role functioning. Cancer-specific dimensions with the largest impact were nausea and fatigue or bowel problems. Utility values of the worst health state (i.e. severe problems on all 10 dimension) were-0.111 (Austria), 0.025 (Italy), and 0.048 (Poland). Country-specific utilities differed for a selection of health states across the continuum. Austrian utilities were systematically lower for moderately and severely impaired health states. Conclusion QLU-C10D cancer-specific utilities can now be calculated in three more countries. Differences between countries indicate that careful consideration is required when using non-country-specific value sets in economic evaluations.

Estimation of an EORTC QLU-C10 Value Set for Spain Using a Discrete Choice Experiment

“…Among the generic items, physical functioning reported the largest decrements followed by pain and role functioning. These findings are in line with those in Germany [ 14 ], Austria, Italy, Poland [ 26 ] and France [ 39 ]. Among the cancer-specific items, nausea reported the largest utility decrement followed by bowel problems, which mimicked the same rank order found in the Austrian valuation study [ 16 ].…”

“…For the conduct of CUAs, it is recommended to use country-specific value sets, as differences in preferences across countries might substantially alter the values obtained [21][22][23] and consequently cost-effectiveness estimates. Hence, valuation studies for the EORTC QLU-C10D have been completed, or are currently being undertaken, in numerous countries, including Canada [24], Germany [14], the United Kingdom [25], Austria, France, Italy, Poland [26], the Netherlands, the United States [14] and Singapore [27]. The current study reports on the EORTC QLU-C10D valuation in Spain.…”

Functional health and symptoms in Spain before and during the COVID-19 pandemic

“…The pre-COVID-19 data were available from another research project on health utility evaluations for EORTC QLU-C10D [ 28 , 29 ] of the Spanish general population. Recruitment took place between July 4 and July 29, 2019, and the survey was completed by N = 1010 participants.…”

The EORTC QLU-C10D was more efficient in detecting clinical known group differences in myelodysplastic syndromes than the EQ-5D-3L

“…Each dimension is described on four severity levels (level 1 = "not at all", level 2="a little", level 3="quite a bit", level 4="very much"). We used the Italian population tariff for utility calculation [39]. The measurement range for the Italian version of the QLU-C10D is 0.025-1.00, for the Australian version -0.096-1.00 and for the UK version -0.083-1.00.…”